article thumbnail

What is RWE in Pharma?

Viseven

It allows us to have insight into how patient characteristics and behavior affect outcomes – thereby, it helps to predict the course progress of the disease, a patient’s response to therapies, or the risk of adverse events. Use of Real-World Evidence in Pharmaceutical Companies.

article thumbnail

How using AI in clinical trials accelerates drug development

Pharmaceutical Technology

The need for new medical treatments and drugs has never been greater. But before pharmaceutical companies can go to market with a breakthrough drug, they need to ensure safety and efficacy through clinical trials. Adverse event detection Adverse events, or unexpected side effects, are a crucial aspect of clinical trials.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

The Use of Artificial Intelligence in the Pharmaceutical Industry

Viseven

From the early beginning of the world’s digitalization, the mainstream media taught us that artificial intelligence is a super complicated mechanism that is supposed to cover human existence hurdles, explain the universe’s secrets, start or prevent a global cataclysm, and other significant events. Clinical Trials.

article thumbnail

Decision Making Has Always Been In My DNA — Regardless If I Have The Right To Make The Call

The Happy PharmD

I always tried to figure out how my choices would affect not only what happened today but how they would impact events several months from now. It looked like the logo of a well-known pharmaceutical company. I looked up their phone number and decided to call the company on the phone. I also try to see the big picture.

article thumbnail

Adherence to NICE criteria for initiation and continuation of treatment with a biologic in atopic dermatitis

Hospital Pharmacy Europe

A patient access scheme or commercial arrangement associated with the NICE guidance is a way for pharmaceutical companies to lower the acquisition cost to the NHS to improve its cost-effectiveness, so enabling patients to gain access to high-cost medicine treatments. The NHS price for dupilumab excluding VAT is £1,264.89